Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677366 | 0.95 | ALDH1A1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6985975 | 0.92 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22305103 | 0.92 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3093680 | 0.85 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL643480 | 0.84 | ALDH1A1 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31334408 | 0.84 | HPGD (0.76) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7848596 | 0.83 | POLB (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9364495 | 0.83 | EPHX2 (0.77) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3093672 | 0.83 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL5337680 | 0.82 | ALDH1A1 (0.67) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996041802-A1 | NOVEL HETEROAROMATIC PIPERAZINES FOR USE AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1996-12-27 | — | — | WO | claimed |
| US-20150359766-A1 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS | UNIV BROWN (US) | 2015-12-17 | — | — | US | disclosed |
| US-20130190402-A1 | Methods Of Treating Autism With mGluR5 Antagonists | EMORY UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-15 | — | — | US | disclosed |
| US-20100210542-A1 | Methods of Treating Disorders with Group I mGluR Antagonists | NIH-DEITR | 2010-08-19 | — | — | US | disclosed |
| US-7648993-B2 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-30 | — | — | US | disclosed |
| EP-2010174-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | The Regents of the University of California (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007124348-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | WO | disclosed |
| US-6890931-B2 | Methods of treating disorders with group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1267869-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TOLERANCE AND DEPENDANCE | GLAXO GROUP LTD (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | disclosed |
| EP-1392363-A2 | COMPOSITIONS AND USES OF MGLUR5 ANTAGONISTS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030195139-A1 | Metabotropic glutamate receptor antagonists for treating tolerance and dependency | CORSI MAURO (IT) | 2003-10-16 | — | — | US | disclosed |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | disclosed |
| EP-1267869-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TOLERANCE AND DEPENDANCE | GLAXO GROUP LIMITED (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002078745-A2 | USE OF MGLUR5 ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF AUTISM, MENTAL RETARDATION, SCHIZOPHRENIA | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2001066113-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS FOR TREATING TOLERANCE AND DEPENDENCY | GLAXO GROUP LIMITED (GB) | 2001-09-13 | — | — | WO | disclosed |
| WO-1996041802-A1 | NOVEL HETEROAROMATIC PIPERAZINES FOR USE AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | GRM5, GRIK5, GRIN1 | CA12 4592/4885CA1 1521/4885CA2 2057/4885 |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | CA12 4405/4885CA1 2386/4885CA2 3269/4885 |
| US-20150359766-A1 | METHODS OF TREATING AUTISM WITH mGluR5 ANTAGONISTS | GRM5, GRIK5, GRIK4 | CA12 2445/4885CA1 867/4885CA2 811/4885 |
| US-20030195139-A1 | Metabotropic glutamate receptor antagonists for treating tolerance and dependency | GRM5, GRIK5, GRM1 | CA12 3506/4885CA1 1620/4885CA2 2887/4885 |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | CA12 4376/4885CA1 2282/4885CA2 3159/4885 |
| US-20100210542-A1 | Methods of Treating Disorders with Group I mGluR Antagonists | GRM5, GRIK5, GRM2 | CA12 4442/4885CA1 1903/4885CA2 2214/4885 |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | CA12 4376/4885CA1 2282/4885CA2 3159/4885 |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | GRM5, GRIK5, GRM2 | CA12 4442/4885CA1 1903/4885CA2 2214/4885 |
| US-20130190402-A1 | Methods Of Treating Autism With mGluR5 Antagonists | GRM5, GRIK5, GRIK4 | CA12 2445/4885CA1 867/4885CA2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.